Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ILK | Q13418 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579668 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL20213971 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL29579216 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL20214200 | 0.89 | THRB (0.44) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL29579221 | 0.88 | ALDH1A1 (0.46) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL20214105 | 0.88 | ALDH1A1 (0.46) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL28343983 | 0.88 | ALDH1A1 (0.41) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL30829463 | 0.87 | PTGDR2 (0.44) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL20214496 | 0.87 | PTGDR2 (0.44) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A | |
| SCHEMBL20213956 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4EL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | claimed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | claimed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | claimed |
| CN-110603254-B | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2023-03-09 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-11192887-B2 | — | — | 2021-12-07 | — | — | US | disclosed |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112770813-A | Methods of treating cancer with substituted pyrrole and pyrazole compounds and diagnosing cancer sensitive to treatment with substituted pyrrole and pyrazole compounds | 班塔姆制药有限责任公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-110603254-A | Substituted pyrazole compounds and methods of using the same for treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2019-12-20 | — | — | CN | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3548482-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bantam Pharmaceutical, LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102453-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AND METHODS OF USING THEM FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BANTAM PHARMACEUTICAL, LLC (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325903-B2 | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases | KRAS, TP53, CCNI | ALDH1A1 355/4885KDM4E 3557/4885L3MBTL1 135/4885 |
| US-20190345152-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNI | ALDH1A1 355/4885KDM4E 3557/4885L3MBTL1 135/4885 |
| US-11192887-B2 | — | KRAS, TP53, CCNE1 | ALDH1A1 207/4885KDM4E 3282/4885L3MBTL1 131/4885 |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | ALDH1A1 335/4885KDM4E 2356/4885L3MBTL1 3603/4885 |
| US-20230076820-A1 | Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative Diseases | KRAS, TP53, NRAS | ALDH1A1 519/4885KDM4E 3227/4885L3MBTL1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.